SPY749.35−0.44%QQQ673.70−0.83%BTC/USD73,667.70−2.11%DIA521.60−0.33%GLD369.42−2.67%TLT80.89−1.31%

Premium Services

NextCure Inc

NXTCNASDAQ

Trade with Public

Trade with Public

$5.97

-0.30-4.78%

Last update: Nov 10, 3:38 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

NextCure (NXTC) Stock Price Target 2026

The average analyst price target for NextCure is $28.40, 375.7% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $15 to $48. The latest change came on May 11, 2026, when LUCID CAPITAL MARKETS initiated coverage of NextCure with a Buy rating and a $25 price target.

The Average Analyst Price Target for NextCure is $28.40.

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$28.40Upside to Avg. PT+375.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for NextCure Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 11, 2026	LUCID CAPITAL MARKETS	Christopher Liu	Initiate	Buy	$25
Nov 7, 2025	Ladenburg Thalmann	Kevin DeGeeter	Upgrade	Neutral→Buy	$18
Jul 15, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$36→$15
Jul 1, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 17, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 7, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$36
Nov 11, 2024	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$96→$48
Aug 2, 2024	Needham	Gil Blum	Maintained	Buy	$48
Jun 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 31, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	Needham	Gil Blum	Maintained	Buy	$48
Mar 22, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$60→$96
Mar 20, 2024	Needham	Gil Blum	Maintained	Buy	$48
Dec 14, 2023	Needham	Gil Blum	PT Cut	Buy	$72→$48

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target

Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $36 to $15.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NextCure, Lowers Price Target to $4

HC Wainwright & Co. analyst Emily Bodnar maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk